GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Inflammation can occur because of conditions ... You could have an underlying medical condition, such as nasal polyps. Also, it’s best to talk with a doctor if you have severe or concerning ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent respiratory diseases.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Nasal Polyps and Polypoid Degeneration in Asthma and Vasomotor Rhinitis The hypothesis that a specific "allergy virus" or "nasal viral infection" may cause nasal and sinus polyposis, asthma and ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Antrochoanal polyps are unilateral nasal polyps that originate from the maxillary sinus and extend into the choana, which is the space behind the nose where it connects to the throat. These polyps ...

18-20 CRSwNP is caused by inflammation of the nasal lining that can lead to soft tissue growths, known as nasal polyps. 9,12 People with CRSwNP experience symptoms such as nasal obstruction, loss of ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...